Table 3.

Disease-free survival and overall survival according to different risk-level groups

	Disease-free survival			Overall survival
Risk level	Low (n = 83)	Intermediate (n = 133)	High (n = 96)	Low (n = 83)	Intermediate (n = 133)	High (n = 96)
Median (95% CI) (months)	NR (81.6-NR)	73.1 (32.1-NR)	15.2 (11.3-22.6)	NR (83.1-NR)	86.1 (64.3-NR)	38.2 (28.2-55.6)
HR (95% CI)	Ref	2.39 (1.34-4.26)	4.94 (2.78-8.76)	Ref	2.09 (1.08-4.02)	4.69 (2.48-8.86)
P		0.003	<0.0001		0.03	<0.0001
Post-operative strategy
Surveillance
N	55	37	21	55	37	21
Median (95% CI) (months)	NR (87.69-NR)	39.26 (13.86-NR)	6.34 (4.47-9.92)	NR (87.69-NR)	64.26 (26.94-NR)	20.07 (7.39-39.95)
Adjuvant chemotherapy
N	28	96	75	28	96	75
Median (95% CI) (months)	81.58 (46.78-NR)	86.14 (32.13-NR)	19.12 (14.06-47.34)	83.12 (63.61-NR)	86.14 (71.26-NA)	39.49 (28.16-71.43)

Median DFS and OS with HR and P value of high- and intermediate-risk patients are compared with low-risk patients considered as the reference. Overall outcomes of patients treated with adjuvant chemotherapy or surveillance only are presented for each level of risk.

CI, confidence interval; DFS, disease-free survival; HR, hazard ratio; NR, not reached; OS, overall survival; Ref, reference.